作者：
Michele,Potashman [1]
;
Katja,Rudell [2]
;
Ivanna,Pavisic [2]
;
Naomi,Suminski [2]
;
Rinchen,Doma [2]
;
Maggie,Heinrich [2]
;
Linda,Abetz-Webb [3]
;
Melissa Wolfe,Beiner [4]
;
Sheng-Han,Kuo [5]
;
Liana S,Rosenthal [6]
;
Theresa,Zesiwicz [7]
;
Terry D,Fife [8]
;
Bart P,van de Warrenburg [9]
;
Giovanni,Ristori [10]
;
Matthis,Synofzik [11]
;
Susan,Perlman [12]
;
Jeremy D,Schmahmann [13]
;
Gilbert,L'Italien [4]
作者单位：
Biohaven Pharmaceuticals, Inc, New Haven, CT, USA. michele.potashman@biohavenpharma.com.
[1]
COA Science, Parexel International, London, UK.
[2]
Patient-Centered Outcomes Assessments, Macclesfield, UK.
[3]
Biohaven Pharmaceuticals, Inc, New Haven, CT, USA.
[4]
Department of Neurology, Columbia University, New York, NY, USA.
[5]
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
[6]
Department of Neurology, Ataxia Research Center, University of South Florida, Tampa, FL, USA.
[7]
Department of Neurology, Barrow Neurological Institute, University of Arizona College of Medicine, Phoenix, AZ, USA.
[8]
Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands.
[9]
Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.
[10]
Division of Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
[11]
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
[12]
Ataxia Center, Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
[13]
DOI
10.1007/s12311-024-01700-2
PMID
38713312
发布时间
2024-10-21
换一批
换一批
